Treatment of Giant Cell Arteritis

Initial Treatment Approach

The American College of Rheumatology recommends starting high-dose oral glucocorticoids (prednisone 1 mg/kg/day, maximum 60 mg/day) immediately upon clinical suspicion of GCA, even before biopsy confirmation, to prevent vision loss and other ischemic complications 1, 2
Daily dosing of glucocorticoids is recommended over alternate-day schedules to achieve higher remission rates 1, 4
For patients with threatened vision loss, administer intravenous pulse methylprednisolone (500-1000 mg/day for 3 days) immediately, followed by high-dose oral prednisone 2, 5

Add tocilizumab to glucocorticoids as first-line therapy, especially for patients at high risk of steroid-related complications, to reduce relapse rates and minimize steroid exposure 1, 2, 3
Consider methotrexate as an alternative steroid-sparing agent if tocilizumab is contraindicated 1, 2, 3
Prescribe low-dose aspirin (75-150 mg/day) for all patients with GCA unless contraindicated, to protect against cardiovascular and cerebrovascular events 6

Maintain initial high-dose glucocorticoids for approximately one month to ensure adequate disease control 3
Begin gradual taper after symptoms are controlled and inflammatory markers have normalized, aiming for 10-15 mg/day by 3 months, and ≤5 mg/day after 1 year 3
Guide tapering by clinical symptoms and normalization of inflammatory markers (ESR, CRP) 3, 4

For patients with disease relapse with symptoms of cranial ischemia, add a non-glucocorticoid immunosuppressive agent (preferably tocilizumab) and increase the dose of glucocorticoids 4, 7
For relapses with symptoms of polymyalgia rheumatica, increasing the dose of glucocorticoids alone may be sufficient 4, 7
For patients with increased inflammatory markers alone without clinical symptoms, clinical observation and monitoring without escalation of immunosuppressive therapy is recommended 4, 7

Obtain noninvasive vascular imaging to evaluate large vessel involvement in newly diagnosed GCA 2
For patients with active extracranial large vessel involvement, oral glucocorticoids combined with a non-glucocorticoid immunosuppressive agent is recommended over oral glucocorticoids alone 1, 2
For patients with severe GCA and worsening signs of limb/organ ischemia, escalate immunosuppressive therapy over immediate surgical intervention 7
Consider immediate surgical intervention for aortic aneurysms at high risk for rupture and impending/progressive tissue or organ infarction 7

Implement long-term clinical monitoring for all patients, even those in apparent remission, to detect potential relapses 4, 7
Monitor inflammatory markers (ESR, CRP) regularly to guide treatment decisions 4, 7

Visual loss occurs in 15-35% of patients with GCA, primarily before initiation of therapy 3, 5
Without treatment, the risk of vision loss in the second eye is as high as 50% if one eye is already affected 5
Glucocorticoid-related adverse events are common with long-term therapy 3

Do not delay treatment while awaiting biopsy results, as vision loss can be permanent 3, 5
Avoid rapid steroid withdrawal as it can lead to disease exacerbation 3
Do not use infliximab for GCA as it is associated with recurrent ocular symptoms and markers of disease activity 8